Sofie Biosciences nets $2M for PET agents, systems development

Manjula Puthenedam, PhD, | | Health Imaging | Molecular Imaging
Sofie Biosciences has raised $2 million from new and existing investors which will be used for the development of new PET imaging agents and systems.

The round includes the first institutional and corporate financing to the firm including investment by the Carpinteria, Calif-based venture capital firm Cycad Group.

The molecular imaging agents are being developed to enable physicians to diagnose disorders in immunology and oncology as well as select the best treatment, said the Culver City, Calif.-based Sofie Biosciences.

Recently, Sofie Biosciences introduced Genisys, a bench-top small animal PET system.

Manjula Puthenedam, PhD,

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.